REG - Tissue Regenix Group - Directorate Change

Tissue RegenixAnnouncement

01/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250801:nRSA4475Ta&default-theme=true

RNS Number : 4475T  Tissue Regenix Group PLC  01 August 2025

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

 

Directorate Change

Appointment of Interim CFO

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that following initial notification at the final results for the year ended 31
December 2024
(https://www.londonstockexchange.com/news-article/TRX/final-results-for-the-year-ended-31-december-2024/17102337)
, David Cocke will retire today from his role as Chief Financial Officer
('CFO'). Brandon Largent, Associate Vice President of Finance at Tissue
Regenix will replace David in a non-board role as Interim CFO with immediate
effect.

 

Brandon has over 25 years' experience leading financial operations across
PE-backed, private and publicly listed companies. Prior to his role as
Associate Vice President of Finance at Tissue Regenix, Brandon was Financial
Planning & Analysis Manager (Commercial Division) for Groundworks, a
provider of patented groundwork solutions, leading a post-acquisition finance
transformation and post-merger integration for Groundworks' entry into the
commercial sector. Brandon has also held positions as CFO of Merlin One
Aircraft, an US$8M private charter aviation firm and as Finance Manager (US
Operations) at Tissue Regenix from 2020-2022.

 

Daniel Lee, CEO of Tissue Regenix, commented: "We are pleased to appoint
Brandon Largent as interim CFO. The Group will undergo a seamless transition
as we benefit from Brandon's working knowledge of Tissue Regenix and his
previous experiences in financial leadership roles."

 

"I would like to congratulate David on a well-earned retirement. David's
contributions and accomplishments have been instrumental in the Company's
growth and success over the past several years. David will be a missed
presence among the Tissue Regenix team, but we wish him much happiness and
every success in his next chapter."

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                via Walbrook PR

 David Cocke, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                             Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAWPUMUMUPAGPG